IGC Pharma, Inc. IGC
0.21 USD 0.00 (+2.50%)
Nov 9, 2026, 1:18 PM EST
0.193 Day range 0.206
0.08 52-week range 0.40
- YTD
- -26.79%
- 1 year
- -44.59%
News
benzinga.com IGC Pharma Receives Patent From Canadian Intellectual Property Office Covering Composition Of IGC-AD1 Therapy For Agitation In Alzheimer IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare
benzinga.com Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket Celestica jumps 16.4% after beating Q3 FY26 estimates and raising guidance; 22nd Century leads premarket gainers at 69.8%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
benzinga.com 'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment https://www.marijuanamoment.net/dea-judge-pauses-marijuana-rescheduling-hearing-as-opponents-highlight-government-report-detailing-gaps-in-federal-processes/
benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
benzinga.com IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per…
benzinga.com IGC Pharma Says CEO Ram Mukunda And Principal Financial Officer Claudia Grimaldi Purchase Aggregate Of 4,274,853 Shares Directly From Company At $0.27/Shr Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGCPOTOMAC, MD / ACCESS…
benzinga.com IGC Pharma Launches AI-Powered Data Harmonization Platform To Accelerate Alzheimer’s Research And Drug Discovery Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in…
benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.5 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.25 to $5.5.- benzinga.com 'White House Pushes Congress To Keep Hemp CBD Products Legal By Amending Broad Ban That's Set To Take Effect Later This Year' - Marijuana Moment https://www.marijuanamoment.net/white-house-pushes-congress-to-keep-hemp-cbd-products-legal-by-amending-broad-ban-thats-set-to-take-effect-later-this-year/
benzinga.com IGC Pharma Announces Addition Of Icahn School Of Medicine At Mount Sinai In New York As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation Associated With Alzheimer's Disease Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysisPOTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma,…- benzinga.com "Marijuana Components Have 'Consistent' Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows" - Marijuana Moment https://www.marijuanamoment.net/marijuana-components-have-consistent-anti-tumor-effec
- benzinga.com 'Trump Reclassifies State-Licensed Medical Marijuana As A Less-Dangerous Drug In A Historic Shift' - AP News https://apnews.com/article/medical-marijuana-rescheduling-justice-department-trump-cannabis-1d6722d3aae122b1a91f8e4b6c690268
- benzinga.com 'Trump Administration Is Expected To Move To Reclassify Marijuana As Soon As Wednesday' - Axios https://www.axios.com/2026/04/22/trump-marijuana-rule-change
- benzinga.com IGC Pharma Adds Kerwin Medical Center In Dallas, Texas As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Disease Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation studyPOTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc.…
- benzinga.com IGC Pharma Receives Authorization In Colombia To Synthesize, Formulate, And Conduct Development Activities Involving Psilocybin At Its R&D Facility In Bogotá Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completionPOTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC…
- benzinga.com IGC Pharma Enrolls ~80% Participants In Its Phase 2 CALMA Clinical Study Of IGC-AD1 For Agitation Associated With Alzheimer's Disease IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated…
- benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.
- benzinga.com 'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire https://cannabiswire.com/newsletters/scoop-medicare-cbd-pilot-will-allow-some-thc-in-products/?free_read=1773920530418
- benzinga.com IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share…
- benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $4.75 to $5.
- benzinga.com 'Federal Agency Finalized Rule For CBD Medicare Coverage Pilot Program Weeks Ago, Key Hemp Stakeholder Says'- Marijuana Moment https://www.marijuanamoment.net/federal-agency-finalized-rule-for-cbd-medicare-coverage-pilot-program-weeks-ago-key-hemp-stakeholder-says/
- benzinga.com 'GOP Congressman Isn't Sure Marijuana Rescheduling Is A DOJ 'Priority,' But Remains Optimistic About Progress Under Trump' - Marijuana Moment https://www.marijuanamoment.net/gop-congressman-isnt-sure-marijuana-rescheduling-is-a-doj-priority-but-remains-optimistic-about-progress-under-trump/
- benzinga.com IGC Pharma Adds Integrative Clinical Trials Site In Brooklyn IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today…
- benzinga.com IGC Pharma Adds Dominion Medical Associates Clinical Research Site With Lightship's Site Network IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's…
benzinga.com 'New Hampshire House Passes Bills To Legalize Marijuana And Let Dispensaries Convert To For-Profit Status' - Marijuana Moment https://www.marijuanamoment.net/new-hampshire-house-passes-bills-to-legalize-marijuana-and-let-dispensaries-convert-to-for-profit-status/- benzinga.com 'Congressional Leaders Drop Attempt To Block Marijuana Rescheduling, While Preserving State Medical Cannabis Protections'- Marijuana Moment https://www.marijuanamoment.net/congressional-leaders-drop-attempt-to-block-marijuana-rescheduling-while-preserving-state-medical-cannabis-protections/
benzinga.com 'Florida Attorney General Asks Supreme Court To Block Marijuana Legalization Measure From Ballot' - Marijuana Moment https://www.marijuanamoment.net/florida-attorney-general-asks-supreme-court-to-block-marijuana-legalization-measure-from-ballot/- benzinga.com 'Federal Health Programs Will Cover Up To $500 Worth Of CBD For Certain Patients By April, Trump Official Dr. Oz Says'- Marijuana Moment https://www.marijuanamoment.net/federal-health-programs-will-cover-up-to-500-worth-of-cbd-for-certain-patients-by-april-trump-official-dr-oz-says/
- benzinga.com 'President Trump Directs Attorney General Pam Bondi to Finalize Marijuana Rescheduling by the End of January'- The Marijuana Herald https://themarijuanaherald.com/2025/12/president-trump-directs-attorney-general-pam-bondi-to-finalize-marijuana-rescheduling-by-the-end-of-january/
- benzinga.com 'Supreme Court Should Uphold Gun Ban For Marijuana Users, 19 State AGs Tell Justices' - Marijuana Moment https://www.marijuanamoment.net/supreme-court-should-uphold-gun-ban-for-marijuana-users-19-state-ags-tell-justices/
benzinga.com Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - benzinga.com IGC Pharma Gets New Patent From U.S. Patent And Trademark Office To Treat Stuttering, Tourette's Syndrome IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease,…
benzinga.com Why MillerKnoll Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - benzinga.com 'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News https://www.nbcnews.com/politics/donald-trump/trump-expected-order-reclassify-cannabis-open-medical-pot-rcna249550
- benzinga.com IGC Pharma Increases Authorized Common Stock To 600M Shares Effective December 12, 2025, IGC Pharma, Inc. (the "Company") amended its Amended and Restated Articles of Incorporation in order to give effect to a previously announced increase of its authorized…
- benzinga.com Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance... " https://x.com/LizClaman/status/2000667074671067347?s=20
- benzinga.com IGC Pharma Highlights AI-Driven Alzheimer's Drug Development Amid Federal Cannabis Schedule III Reclassification Momentum IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today…
- benzinga.com IGC Pharma Reaches Key Enrollment Milestone Of 65% For Ongoing Phase 2 CALMA Clinical Trial Evaluating IGC-AD1 For Treatment Of Agitation In Alzheimer's Disease IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment https://www.marijuanamoment.net/nebraska-supreme-court-hears-case-seeking-to-overturn-medical-marijuana-law-approved-by-voters/
- benzinga.com IGC Pharma Highlights Publication Of Caregiver Book On Alzheimer's Disease This book represents an essential contribution to the global Alzheimer's community," said Ram Mukunda, CEO of IGC Pharma. "Our diverse pipeline of candidates, including IGC-AD1, currently advancing…
- benzinga.com UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors
- benzinga.com 'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment https://www.marijuanamoment.net/marijuana-banking-bill-is-on-the-back-burner-as-congressional-lawmakers-see-no-indication-itll-advance-soon/
- benzinga.com 'GOP Representative Brian Mast Signs On As Sponsor Of Bipartisan Legislation To Reschedule Cannabis' - Marijuana Herald https://themarijuanaherald.com/2025/11/gop-mast-reschedule-cannabis/
- benzinga.com IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales…
- benzinga.com IGC Pharma Granted Patent From USPTO For Propriety Formulation Used In IGC-AD1 Drug Candidate For Agitation In Alzheimer's Disease IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for…
- benzinga.com IGC Pharma Will Be Issued U.S. Patent Number 12,465,589 Tomorrow Titled "METHOD AND COMPOSITION FOR TREATING CNS DISORDERS (SPECIFICALLY ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE)" https://patentcenter.uspto.gov/applications/18301099/ifw/docs
- benzinga.com IGC Pharma Expands AI-Powered In-Silico Platform To Accelerate Alzheimer's Drug Discovery IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced an…
- benzinga.com IGC Pharma Expands Ongoing Phase 2 CALMA Clinical Trial Evaluating Investigational Drug Candidate IGC-AD1 For Agitation In Alzheimer's Disease IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced the…